Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition
eLife · 10.11.2026 · 15
DOI: 10.7554/elife.110991 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 10.11.2026. Verfasst von Chiara Asselborn und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Hypoxia-Inducible Factor-Proline Dioxygenases, Glutathione S-Transferase pi, Triazoles. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, European Research Council, Medical Research Council.
Abstract (Originalsprache)
Mutations in the adenomatous polyposis coli (APC) gene are a defining feature of colorectal cancer (CRC) and impose metabolic and stress adaptation requirements that may create exploitable vulnerabilities. Prolyl hydroxylase domain (PHD) inhibitors have been explored as therapeutic agents in CRC; however, their mechanisms of action and off-target effects remain elusive. Serendipitously, we found that Molidustat, a PHD2 inhibitor, induced cell death in human APC-mutant CRC cells. Ablation of PHD2 alone did not affect cell viability, suggesting an off-target mechanism. Using thermal proteome profiling and chemical proteomics, we identify glutathione S-transferase P1 (GSTP1) as a previously unrecognised off-target of Molidustat and demonstrate direct inhibition of its enzymatic activity. Genetic ablation of PHD2 alone did not phenocopy the cytotoxic effects of Molidustat, whereas combined loss of PHD2 and GSTP1 induced synergistic proteomic changes associated with cell-cycle suppression and apoptotic signalling. Integrated proteomic and metabolomic analyses further revealed energetic and metabolic perturbations specific to simultaneous GSTP1 and PHD2 loss. Consistent with these findings, APC-mutant mouse organoids displayed selective sensitivity to Molidustat that was not reproduced by hydroxylase inhibition alone, supporting a synthetic lethal interaction between GSTP1 and PHD2 in APC-mutant contexts. Together, these results identify a functional interaction between GSTP1 and PHD2 in a subset of CRC and suggest that off-target engagement of GSTP1 contributes to the anti-tumour activity of Molidustat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.
- Technische Universität Berlin, Si-M/'Der Simulierte Mensch', a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany.
ORCID-Profile: Chiara Asselborn, Agata N Makar, Alex von Kriegsheim
Förderung
- Cancer Research UK
- European Research Council
- Medical Research Council
- Biotechnology and Biological Sciences Research Council
- Wellcome Trust
Zitieren
APA
Asselborn, C., Makar, A. N., Marques Junior, J. G., Akan, A. B., Yiapanas, A., Jennings, C., Perez-Lopez, A., Wills, J., Unciti-Broceta, A., Myant, K. B., & von Kriegsheim, A. (2026). Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition. eLife, 15. https://doi.org/10.7554/elife.110991
Vancouver
Asselborn C, Makar AN, Marques Junior JG, Akan AB, Yiapanas A, Jennings C, et al. Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition. eLife. 2026;15. doi:10.7554/elife.110991
BibTeX
@article{Asselborn2026,
author = {Asselborn, Chiara and Makar, Agata N and Marques Junior, Jair G and Akan, Aslihan Bastem and Yiapanas, Athanasia and Jennings, Carrie and Perez-Lopez, Ana and Wills, Jimi and Unciti-Broceta, Asier and Myant, Kevin B and von Kriegsheim, Alex},
title = {Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition},
journal = {eLife},
year = {2026},
volume = {15},
doi = {10.7554/elife.110991}
}
EUVIMED